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Abstract
Background: Indoleamine 2,3-dioxygenase (IDO) is a tryptophan catalyzing enzyme. It has been suggested that it
has a role in lower airway allergic inflammations, but its role in allergic rhinitis has not been investigated.
Objective: Our aim was to evaluate the expression of IDO in the nasal mucosa of allergic rhinitis patients allergic
to birch pollen during peak exposure to birch pollen allergen and compare it to non-atopic patients.
Methods: IDO expression was immunohistochemically evaluated from nasal specimens obtained in- and off-season
from otherwise healthy non-smoking volunteers both allergic to birch pollen (having mild or moderate allergic
rhinoconjunctivitis) and non-allergic controls.
Results: The IDO expression levels were low in healthy controls and remained low also in patients allergic to birch
pollen. There were no differences in the expression of IDO in- and off-season in either healthy or allergic subjects.
Conclusions: There is a controversy in the role of IDO in upper and lower airways during allergic airway disease. It
seems that IDO is associated to allergic inflammations of the lower airways, but does not have a local role in the
nasal cavity at least in mild or moderate forms of allergic rhinitis.
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Introduction
Indoleamine 2,3 dioxygenase (IDO) is an intracellular
enzyme that initiates the first and rate-limiting step of
tryptophan breakdown along the kynurenine pathway [1].
IDO is widely expressed in a variety of cell types including
leukocytes and tumour cells [2]. Initially the role of IDO
was thought to be mainly antimicrobial by reducing the
availability of the essential amino acid tryptophan in the
inflammatory environment [3]. In the past years, IDO has
emerged as an important regulator of the immune system;
however, it is not known whether local IDO activity is
beneficial or detrimental to inflamed tissues. IDO is
induced by interferon g (IFN-g) and other inflammatory
cytokines during inflammation or as a consequence of
normal tissue function [4]. IDO suppresses T cell activity
and promotes T cell tolerance to further antigenic chal-
lenges, by promoting the differentiation of naïve CD4 T
cells into regulatory T cells, putatively by regulation by
dendritic cells [5-10]. IDO seems to serve as a negative
feedback loop or is not essential for Th1 responses, but
plays a distinct role in up-regulating Th2 dominant
immune responses [2,11]. Moreover, IDO has also been
shown to down-regulate Th2 responses [12]. The role of
IDO in the modulation of allergic airway inflammation has
recently been investigated [13-16].
Our objective was to observe IDO expression levels in
the nasal mucosa of allergic rhinitis patients allergic to
birch pollen in relation to exposure to birch pollen aller-
gen and compare it to healthy controls.
Materials and methods
Subjects
This study is a case-control study. It was carried out at the
Department of Otorhinolaryngology, Tampere University
Hospital, Finland and has been approved by the Hospital’s
Ethical committee. Written informed consent was
obtained from all patients. The subjects were Caucasian.
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symptoms, or non-atopic. Moreover, the patients did not
have other diseases such as asthma. The diagnosis of birch
pollen-induced allergic rhinitis was based on a history of
seasonal allergic rhinitis during spring, clinical examina-
tion, and skin prick test positivity. Characteristics of the
subject groups are shown in table 1. Specimens were
taken from the nasal cavity. Biopsies from the anterior
edge of the inferior turbinate were obtained with Fokkens’
forceps under local anaesthesia. Specimens were taken
during both winter (off season) and during peak allergen
exposure in spring (in season, natural allergen exposure).
Patients were not allowed to use their medication (antihis-
tamine and/or nasal corticosteroids) for a minimum of 5
days before nasal biopsies were taken.
Sample staining
Nasal specimens were immediately snap-frozen in liquid
nitrogen and stored at -80°C until analysis. Tissue
samples were stained with hemalaun-eosin to calculate
the number of mucosal leukocytes and eosinophils/mm
2
and to evaluate the inflammation score (0 = no inflam-
mation, 1 = mild, 2 = moderate, 3 = severe inflamma-
tion) For light microscope evaluation,
immunoperoxidase staining was used and specimens
were cut into 3-5 μm thick frozen sections on Super-
frost Plus microscope slides. (Menzel-Gläser, Braunsch-
weig, Germany). Frozen sections were fixed with
formalin during 45 minutes. Fully automated immunos-
taining was performed byV e n t a n aB e n c h M a r kL T
Automated IHC Stainer (Ventana Medical System, Ari-
zona, USA). Ultraview Universal DAB detection kit (cat-
alogue No. 760-500, Ventana Medical System, Arizona,
USA) was used. For epitope retrieval CC1: Tris -EDTA
buffer pH 8.0 (catalogue No 950-124, Ventana) was
used at 95°C to 100°C for 8 minutes. Endogenous perox-
idase was blocked with UV-Inhibitor 3% H202 (Ven-
tana) for 4 minutes at 37°C. Tissue slides were rinsed
Table 1 Patient characteristics
Control
n=1 5
Atopy
n=1 2
P value
Age
median 23 24.5 NS
min-max 21-36 21-34
No. of male sex 4 5 NS
Peripheral blood eosinophils
median 0.23 0.15 NS
Q1-Q3 0.085-0.295 0.12-0.20
% of peripheral blood eosinophils
median 3.0 2.5 NS
Q1-Q3 2.0-4.0 2.0-4.0
S-IgE
median 27.0 182.0 < .001
Q1-Q3 18.5-58.5 67.0-410.0
IgE birch
median < .35 62.5 < .001
Q1-Q3 < .35- < .35 12.0-161.0
IgE timothy grass
median < .35 4.75 < .001
Q1-Q3 < .35- < .35 1.6-.6.1
No. subjects having SPT positivity to any basic allergen 0 12 < .001
birch 0 12 < .001
timothy grass 0 9 < .001
other pollen 0 12 < .001
animal dander 0 9 < .001
house dust mite 0 0 NS
other basic allergens 0 0 NS
Biopsies were taken during
winter 11 8 NS
spring 7 11 .019
both 3 7 NS
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(catalogue No. 950-300, Ventana). Slides were incubated
at 37°C for 32 minutes with mAb anti-Indoleamine 2,3
dioxygenase (1:200, clone MAB5412, Chemicon Interna-
tional Inc., USA) followed by application of Ventana
Ultraview HRP Universal Multimer (8 minutes at 37°C).
Diaminobenzidine (DAB) was used as a chromogen and
haematoxylin as a nuclear stain. Known positive tissue
samples (from coeliac or inflammatory bowel disease)
were also used to confirm the staining reliability of all
separate staining patches [17,18]. The specificity of
immunohistochemistry was controlled by omitting the
primary antibodies or replacing them with irrelevant
antisera.
Light microscopic evaluation
Sections were examined with a Leica DM 2000 light
microscope (Leica Microsystems GmbH, Wetzlar, Ger-
many) by two independent observers blinded to the
experimental conditions. In a sample, there was either
moderate or strong immunoreactivity of all epithelial
cells or no epithelial positivity at all. Thus, the results
were expressed as IDO positive epithelium or IDO nega-
tive epithelium. The percentage of IDO positive mucosal
leukocytes was counted.
Data analysis
Statistical analysis was carried out by SPSS Base 15.0
Statistical Software Package (SPSS Inc., Chicago, IL,
USA). Data is expressed as medians or means. For com-
parisons, the results were analysed by, Fisher’se x a c t
(discrete) or Kruskal Wallis and Mann Whitney U tests
(continuous). For pair-wise comparisons McNemar’s
and Wilcoxon tests were used. Two-tailed P-values of <
0.05 were considered statistically significant.
Results
IDO was expressed in the vicinity of the Golgi appara-
tus of epithelial cells, but not on the supraepithelial
mucus. IDO was additionally expressed weakly in sub-
mucosal leukocytes and in intraepithelial glands. When
observing the nasal biopsies, the number of specimens
having positive epithelial IDO staining was not asso-
ciated with atopy during either winter or spring (P >
0.05 by Fisher’s test, Table 1, Figure 1). The percentage
of IDO positive leukocytes did not associate with atopy
in specimens taken during either winter or spring (P >
0.05, by Kruskal-Wallis test, Table 2, Figure 1). Nor
did it associate with the expression of IDO in the
epithelium (P > 0.05, by Kruskal-Wallis test, data not
shown). The subjects did not have changes in the
epithelial IDO expression or in the percentage of IDO
positive leukocytes when comparing specimens taken
during winter and spring from the same individuals (P
> 0.05, by Wilcoxon test, Table 2). The median num-
ber of mucosal eosinophils was significantly higher in
atopic than in non-atopic subjects only during sympto-
matic spring (P = 0.044, by Kruskal-Wallis and Mann
Whitney U test, table 2), whereas the percentage of
eosinophils did not significantly differ between atopic
and non-atopic subjects (P > 0.05, by Kruskal-Wallis
test, table 2). Interestingly, during spring the number
of mucosal leukocytes and the percentage of IDO posi-
tive leukocytes correlated significantly (P < 0.05, r =
0.46, by Spearman rank correlation test, data not
shown).
As expected, atopics had significantly increased serum
IgE levels (p < 0,001, by Kruskal-Wallis, Mann Whitney
U). Atopic subjects had a significantly increased median
symptom score during symptomatic spring in compari-
son to asymptomatic winter (P = 0.031, by Wilcoxon
test, table 2), whereas in the non-atopic subjects, the
median symptom score in winter and spring did not
vary (P > 0.05, by Wilcoxon test, table 2). Accordingly,
the median symptom score was significantly higher in
the atopic than in the non-atopic group during spring
but did not differ during winter (P = 0.003, P > 0.05,
respectively, by Fisher’s exact test, table 2).
Discussion
We aimed to evaluate IDO expression in two well
defined human phenotypes: controls and their atopic
counter-parts. Skin prick tests (SPT) were performed on
Figure 1 The expression of indoleamine 2,3-dioxygenase (IDO)
in biopsies from the nasal cavity. (A) Nasal mucosa taken from a
patient with allergic rhinitis off-season (during winter). No epithelial
or leukocyte expression of IDO. (B) Specimen from another patient
with allergic rhinitis, taken off-season, has epithelial IDO
+ and
leukocyte IDO
-. (C) The same allergic rhinitis patient as in frame A,
did not display any IDO expression in the specimen taken in-season
(during spring). (D) Specimen from a healthy patient, taken off-
season, shows epithelial IDO
- and leukocyte IDO
+. Original
magnification 200× (A, B, D) and 400× (C).
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atopic groups did not differ in terms of patient number,
age, sex, peripheral blood eosinophils, percentage of per-
ipheral blood eosinophils. (p > 0,05 Kruskal-Wallis,
Mann Whitney U) In comparison to controls, atopics
had significantly higher serum IgE levels as well as sig-
nificantly higher IgE levels against allergens to which
the subjects were allergic. Atopics and controls differed
in their symptom score only during the spring (in sea-
son, natural allergen exposure). Surprisingly, there were
no differences between inflammation score, leukocyte
numbers, percentages of eosinophils, IDO+ in epithelial
cells and leucocytes during winter (off season) and
spring. Atopics had a higher number of eosinophils dur-
ing spring only.
We observed that in the nasal cavity, expression of IDO
was low and did not differ between atopic and non-atopic
groups. Moreover IDO expression did not fluctuate in
the same individuals between symptomatic spring and
asymptomatic winter season. We have also previously
shown that the role of the nasal epithelium in birch pol-
len atopy is important [19]. In contrast others have
shown that IDO might have a role in atopy. Paveglio et
al. very recently showed in a transgenic mouse model
that over-expression of IDO in the lungs might cause an
anti-asthmatic effect by diminishing proliferation, num-
bers and cytokine production of CD4 + T cells [20].
Others have also previously shown that after in vivo aero-
allergen exposure, serum IDO activity was increased in
asymptomatic atopics compared with either symptomatic
atopic or non-atopic individuals [21]. When exposing in
vitro monocyte-derived dendritic cells with house dust
mite Dermatophagoides pteronyssinus 1, functionally
active IDO decreased in cells from patients with house
dust mite-sensitive asthma compared to non-atopic asth-
matics [15]. In asthmatic patients, the baseline IDO activ-
ity in sputum has been shown to be significantly lower
than control levels, but normal baseline activity in asth-
matic patients could be induced by using inhaled corti-
costeroids [22]. We have previously demonstrated that a
high expression of epithelial and leukocyte IDO is asso-
ciated with chronic rhinosinusitis with nasal polyps,
while the expression in chronic rhinosinusitis without
nasal polyps remained at the control level [23]. Thus in
the upper airways, in contrast to lower airways, it seems
that IDO might have a role in the nasal polyp pathome-
chanisms instead of atopy. Yet, more studies are required
to bring evidence on this.
The expression of IDO differs between tissues [24].
Recently, two isoforms of IDO have been studied, IDO1
Table 2 Characteristics of nasal specimens
Control
winter
n=7
spring
n=1 1
P value
1 Atopy
winter
n=1 1
spring
n=8
P value
1 P value
2
Symptom score
median 0 0 NS 0 2.0 .031 w NS*
Q1-Q3 0-0 0-0 0-0 1-2 s .003*
Inflammation score
median 1.5 1.5 NS 1.0 1.5 NS w NS*
Q1-Q3 1-2 1-2 1-2 1-3 s NS*
No. of leukocytes/mm
2
median 640 1328 NS 1344 1328 NS w NS
Q1-Q3 384-896 1280-1376 1120-1408 992-1760 s NS
No. of eosinophils/mm
2
median 96 168 NS 144 248 NS w NS
Q1-Q3 48-144 112-224 128-160 192-448 s .044
Percentage of eosinophils
median 14.3 12.5 NS 12.0 25.5 NS w NS
Q1-Q3 12.5-16.1 8.8-16.3 9.1-12.5 12.9-29.0 s NS
Percentage of IDO
+ eosinophils
median 0.0 0.0 NS 0.0 0.0 NS w NS
Q1-Q3 0.0-0.0 0.0-0.0 0.0-2.5 0.0-5.5 s NS
No. specimens with
epithelial IDO
+ 2 2 NS 1 2 NS w NS*
s NS*
Patient characteristics and results of specimens taken from the nasal cavity. Control = mucosa from inferior turbinate from patient without inflammation of nasal
mucosa and without sinonasal disease, P value
1 = by pair-wise comparison between winter and spring by Wilcoxon test; P value
2 = comparison between control
and atopy groups either in winter (w) or in spring (s) by *Fisher’s exact test (discrete) or Kruskal Wallis test (continuous).
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differs in different tissues and in same cell cultures [25].
Both isoforms therefore might differ somehow in their
roles [26,27]. Having this in mind, it could be possible
that the anti-IDO mAb we used could be specific only
for the IDO1 isotope [27]. Also, in some tissues IDO
expression does not correlate with its activity. Indeed,
elevated expression of IDO can translate into little activ-
ity or no activity at all [24]. Even though high levels of
IDO expression can be measured, this does not necessa-
rily translate into activity measured by ratio of trypto-
phan over kynurenine.
Both atopic asthma and atopic rhinitis are complex
diseases with different phenotypes and genetic back-
grounds. Currently it is thought that patients with cer-
tain (epi)genetic elements are prone to have
immunological dysfunctions of respiratory barriers puta-
tively by stimulation by certain environmental interac-
tions [28]. Thus, our findings suggest that adult patients
with only birch pollen AR but not asthma symptoms do
not have local IDO. In the future, it would be of interest
to observe whether immunological factors differ in
patients having only the AR phenotype compared to
those with the AR and asthma phenotype [29].
Conclusions
This study showed that in the nasal cavity, epithelial and
leukocyte IDO expression is low and is not associated to
allergic rhinitis caused by birch pollen. There is a con-
troversy in the role of IDO in the pathogenesis of atopy,
between upper and lower airways. More human studies
are warranted to study the role of IDO in more detail in
allergic rhinitis and other atopies.
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